#concept #genomics #biotech #diagnostics

# Genomics

Gene sequencing, editing, and diagnostics — enabling precision medicine, drug discovery, and disease prevention.

---

## Market overview

| Segment | 2025 market | 2035E | CAGR |
|---------|-------------|-------|------|
| Total genomics | ~$46B | ~$187B | 15% |
| Sequencing | ~$8B | ~$25B | 12% |
| Gene editing | ~$11B | ~$45B | 17% |
| Genetic diagnostics | ~$20B | ~$60B | 12% |

**US market:** $12B (2024) → $57B (2034)

---

## Key segments

### Sequencing platforms

| Company | Technology | Market share |
|---------|------------|--------------|
| [[Illumina]] | Short-read NGS | **80%** |
| PacBio | Long-read | ~10% |
| Oxford Nanopore | Portable long-read | ~5% |
| [[10x Genomics]] | Single-cell | Niche leader |

**Trend:** NovaSeq X halving sequencing costs, $200 genome approaching.

### Gene editing (CRISPR)

| Company | Focus | Status |
|---------|-------|--------|
| [[CRISPR Therapeutics]] | Casgevy (SCD, TDT) | **FDA approved** |
| Intellia | In vivo editing | Phase 3 |
| Beam Therapeutics | Base editing | Clinical trials |
| Editas | Ocular diseases | Clinical trials |
| Prime Medicine | Prime editing | Early stage |

**Milestone:** Casgevy = first CRISPR therapy approved (Dec 2023).

### Liquid biopsy / Cancer diagnostics

| Company | Product | Application |
|---------|---------|-------------|
| [[Guardant Health]] | Shield, Guardant360 | CRC screening, tumor profiling |
| [[Natera]] | Signatera | MRD monitoring |
| [[Exact Sciences]] | Cologuard, Cancerguard | CRC, multi-cancer |
| Foundation Medicine | FoundationOne | Tumor profiling ([[Roche]]) |
| Grail | Galleri | Multi-cancer detection (Illumina) |

### Prenatal testing (NIPT)

| Company | Product | Market position |
|---------|---------|-----------------|
| [[Natera]] | Panorama, Fetal Focus | Market leader |
| [[Illumina]] | VeriSeq | Strong #2 |
| Myriad | Prequel | Growing |
| Labcorp | MaterniT | Legacy player |

---

## Technology trends

| Trend | Impact |
|-------|--------|
| **$200 genome** | Population-scale sequencing viable |
| **Long-read sequencing** | Structural variants, complex regions |
| **Single-cell** | Cell-level resolution |
| **Spatial genomics** | Tissue architecture + expression |
| **AI + genomics** | Variant interpretation, drug targets |
| **In vivo editing** | No cell extraction needed |

---

## Key applications

| Application | Stage | Key players |
|-------------|-------|-------------|
| **Oncology** | Commercial | Guardant, Foundation, Natera |
| **Prenatal** | Commercial | Natera, Illumina |
| **Rare disease** | Growing | Illumina, clinical labs |
| **Pharmacogenomics** | Emerging | Clinical integration |
| **Population health** | Scaling | [[UK]] Biobank, All of Us |
| **[[Agriculture]]** | Growing | Corteva, Bayer |

---

## Regulatory milestones

| Date | Event |
|------|-------|
| Dec 2023 | **Casgevy FDA approval** (first CRISPR therapy) |
| Jul 2024 | Shield FDA approval (first blood CRC screen) |
| Jan 2025 | Casgevy approved in 8+ countries |
| Apr 2025 | Shield Medicare coverage ($1,495) |
| Sep 2025 | Cancerguard launch (50+ cancer types) |

---

## Reimbursement landscape

| Test | Medicare rate |
|------|---------------|
| Shield (Guardant) | $1,495 |
| Signatera (Natera) | ~$1,175 ASP |
| Cologuard (Exact) | ~$500 |
| Guardant360 | ~$3,500 |

**Trend:** Expanding coverage for liquid biopsy, MRD testing.

---

## Investment themes

| Theme | Expression |
|-------|------------|
| Sequencing dominance | [[Illumina]] (80% share) |
| Gene editing | [[CRISPR Therapeutics]], [[Vertex]] |
| Cancer diagnostics | [[Guardant Health]], [[Exact Sciences]] |
| MRD monitoring | [[Natera]] (Signatera) |
| Multi-cancer detection | Grail (Illumina), Cancerguard (Exact) |

---

## Key metrics

| Metric | What it measures |
|--------|------------------|
| **Test volume** | Adoption/scale |
| **ASP** | Average selling price |
| **Sensitivity/specificity** | Clinical performance |
| **Reimbursement rate** | Payer acceptance |
| **Clinical utility** | Outcomes improvement |

---

## Risks

| Risk | Impact |
|------|--------|
| **Reimbursement** | Coverage decisions critical |
| **Competition** | Multiple liquid biopsy entrants |
| **Clinical adoption** | Physician behavior change |
| **Regulatory** | FDA pathway uncertainty |
| **[[China]] exposure** | Illumina impacted by restrictions |

---

## Public genomics exposure

| Company | Ticker | Focus |
|---------|--------|-------|
| [[Illumina]] | ILMN | Sequencing platforms |
| [[CRISPR Therapeutics]] | CRSP | Gene editing |
| [[Exact Sciences]] | EXAS | Cancer screening |
| [[Natera]] | NTRA | NIPT, MRD |
| [[Guardant Health]] | GH | Liquid biopsy |
| [[10x Genomics]] | TXG | Single-cell |
| [[Vertex]] | VRTX | Casgevy partner |
| PacBio | PACB | Long-read |
| Beam Therapeutics | BEAM | Base editing |
| Intellia | NTLA | In vivo CRISPR |

---

## Related

- [[Illumina]] — sequencing leader
- [[CRISPR Therapeutics]] — gene editing pioneer
- [[Exact Sciences]] — Cologuard, Cancerguard
- [[Natera]] — NIPT, Signatera MRD
- [[Guardant Health]] — liquid biopsy
- [[Vertex]] — Casgevy partner
- [[Tempus]] — AI + genomics
- [[Biopharma]] — sector context
- [[AI drug discovery]] — related concept

---

## Sources

- [MarketsandMarkets Genomics](https://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html)
- [CRISPR Clinical Trials 2025](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)
- [Guardant Shield FDA](https://www.fda.gov/medical-devices/recently-approved-devices/shield-p230009)

*Created 2026-01-09*
